Lorigerlimab, a bispecific PD-1×CTLA-4 DART molecule in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase 1 expansion (exp) cohort.

Jason J.  Luke

Stock and Other Ownership Interests  - Actym Therapeutics; Alphamab; Arch Oncology; Kanaph Therapeutics; Mavu Pharmaceutical; NeoTX; NeoTX; Onc.AI; Pyxis; STipe Therapeutics; Tempest Therapeutics

Consulting or Advisory Role - 7 Hills Pharma; Abbvie; Alnylam; Alphamab; Bayer; Bright Peak Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Codiak Biosciences; Crown Bioscience; CStone Pharmaceuticals; Day One Therapeutics; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Genentech; Gilead Sciences; Hotspot Therapeutics; Immunocore; Incyte; Inzen Therapeutics; Janssen; Kadmon; KSQ Therapeutics; Merck; Nektar; Novartis; Onc.AI; Partner Therapeutics; Pfizer; Reflexion Medical; Regeneron; Ribon Therapeutics; Rubius Therapeutics; SERVIER; Silicon Therapeutics; STINGthera; STipe Therapeutics; Synlogic; Synthekine; Tempest Therapeutics; Tesaro; TRex Bio; Werewolf Therapeutics; Xencor; Xilio Therapeutics

Research Funding - Abbvie (Inst); Agios (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); EMD Serono (Inst); Fstar (Inst); Genmab (Inst); Ikena Oncology (Inst); Immatics (Inst); Incyte (Inst); Kadmon (Inst); KAHR Medical (Inst); Macrogenics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Nektar (Inst); NextCure (Inst); Numab (Inst); Replimune (Inst); Rubius Therapeutics (Inst); Scholar Rock (Inst); Spring bank (Inst); Synlogic (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Trishula Therapeutics (Inst); Xencor (Inst)

Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)

Travel, Accommodations, Expenses - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Janssen; Merck; Mersana; Novartis; Pyxis; Reflexion Medical; Xilio Therapeutics

Manish  Sharma

Stock and Other Ownership Interests  - Abbott Laboratories; Abbvie; Alexion Pharmaceuticals; Amgen; Biogen; Bristol-Myers Squibb; Lilly; Medtronic; Merck; Pfizer; Regeneron

Research Funding - Abbvie (Inst); Agenus (Inst); Alexo Therapeutics (Inst); Alpine Immune Sciences (Inst); Arrys Therapeutics (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Compugen (Inst); Constellation Pharmaceuticals (Inst); Coordination Pharmaceuticals (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Epizyme (Inst); Exelixis (Inst); Forty Seven (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline/Tesaro (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); InhibRx (Inst); Innovent Biologics (Inst); Jounce Therapeutics (Inst); KLUS Pharma (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); NGM Biopharmaceuticals (Inst); Odonate Therapeutics (Inst); Onconova Therapeutics (Inst); Pfizer (Inst); PureTech (Inst); Regeneron (Inst); Samumed (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Shattuck Labs (Inst); Symphogen (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)

Sreenivasa R  Chandana

Consulting or Advisory Role - Amgen; AstraZeneca; Dicephera Pharmaceuticals, Inc.; E.R. Squibb  Sons, LLC; Johnson & Johnson/Janssen; Lilly

Speakers' Bureau - Amgen; Eisai; Ipsen; Johnson & Johnson; Novartis

Research Funding - Abbvie (Inst); Alexion Pharmaceuticals (Inst); Alexo Therapeutics (Inst); ArQule (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Constellation Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Dicerna (Inst); Formation Biologics (Inst); Forty Seven (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Pfizer (Inst); Regeneron (Inst); Symphony Evolution (Inst); TaiRx, Inc. (Inst)

Iwona A.  Lugowska

Honoraria - Agenus; Bristol Myers Squibb Foundation; MSD; Novartis; Roche; Ryvu Therapeutics

Consulting or Advisory Role - MSD

Research Funding - Agenus (Inst); Janssen (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst); Ryvu Therapeutics (Inst)

Travel, Accommodations, Expenses - MSD

Cezary  Szczylik

No Relationships to Disclose

Jakub  Zolnierek

No Relationships to Disclose

Gregory Michael  Cote

Consulting or Advisory Role - BioAtla; C4 Therapeutics; Eisai; Foghorn Therapeutics; Ikena Oncology

Research Funding - Agios (Inst); Bavarian Nordic; Bayer (Inst); C4 Therapeutics (Inst); CBA Research (Inst); Eisai (Inst); Epizyme (Inst); Foghorn Therapeutics (Inst); Jazz Pharmaceuticals (Inst); Macrogenics (Inst); Merck KGaA (Inst); PharmaMar (Inst); Repare Therapeutics (Inst); Springworks Therapeutics (Inst); Sumitomo Dainippon Pharma Oncology (Inst)

Charlene  Mantia

Research Funding - Bristol-Myers Squibb (Inst)

Rafal  Dziadziuszko

Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Novartis; PFIZER; Roche/Genentech; Seagen; Takeda

Consulting or Advisory Role - Karyopharm Therapeutics; Regeneron

Travel, Accommodations, Expenses - AstraZeneca; Roche

Rachel E.  Sanborn

Honoraria - Amgen; AstraZeneca

Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Daiichi Sankyo/Lilly; EMD Serono; Genentech/Roche; GlaxoSmithKline; Janssen Oncology; Macrogenics; Mirati Therapeutics; Regeneron; Sanofi/Aventis

Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); MedImmune (Inst); Merck

Travel, Accommodations, Expenses - AstraZeneca

Denise  Casey

No Relationships to Disclose

Lori  Long

Employment - MacroGenics

Stock and Other Ownership Interests  - MacroGenics

Ashley  Ward

Employment - Foundation Medicine; MacroGenics

Stock and Other Ownership Interests  - MacroGenics; Roche

Patrick  Kaminker

Employment - MacroGenics

Stock and Other Ownership Interests  - MacroGenics

Research Funding - MacroGenics

Angela Joubert  James

Patents, Royalties, Other Intellectual Property - MagroGenics

Tiziana  Di Pucchio

Employment - MacroGenics

Stock and Other Ownership Interests  - MacroGenics

Research Funding - MacroGenics

Bożena  Cybulska-Stopa

Honoraria - MSD; Novartis; Pierre Fabre

Consulting or Advisory Role - MSD

Speakers' Bureau - Bristol Myers Squibb Foundation; MSD; Novartis; Pierre Fabre

Travel, Accommodations, Expenses - MSD; Novartis; Pierre Fabre